GENE ONLINE|News &
Opinion
Blog

2020-03-24| COVID-19

Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment

by Ruchi Jhonsa
Share To

By Ruchi Jhonsa, Ph.D.

While the clinical trials of this promising drug against SARS-CoV-2 are still on, the FDA has provided a significant advantage to Gilead’s remdesivir today. In an announcement made this evening by the U.S. Food and Drug Administration, the agency has granted orphan drug designation to this promising experimental antiviral, a drug touted by the Trump government for COVID-19 treatment. This designation will grant Gilead Sciences, tax incentives as well as seven years of market exclusivity for drug production.

Remdesivir was already provided to patients with a severe infection on a compassionate use basis but ‘overwhelming demand’ in the past weeks forced the company to temporarily suspend drug access. This was after the news circulated about the recovery of the first coronavirus patient who happened to be under remdesivir treatment. Solid evidence from clinical trials in the coming months will tell us whether remdesivir could actually live up to its hype.

References
  1. https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label-idUSKBN21A3PR
  2. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=739020
  3. https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Novavax, Takeda, and BMS To Cut Employees This Year
2023-05-10
Gilead’s HDV Drug Headed Towards European Approval Even With FDA Rejection
2023-05-08
LATEST
BIO 2023 Coming to Boston, with Over 60 Taiwanese Organizations to Share their Achievements
2023-06-02
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications
2023-06-02
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
Scroll to Top